Thomas Seisen1,2, Shahrokh F Shariat3, Olivier Cussenot2,4, Benoit Peyronnet5, Raphaële Renard-Penna6, Pierre Colin7, Morgan Rouprêt8,9. 1. Academic Department of Urology, Pitié-Salpêtrière Hospital, APHP, 47-83 boulevard de l'hopital, 75013, Paris, France. 2. GRC - UPMC n° 5, ONCOTYPE-URO, Institut Universitaire de Cancérologie, UPMC University Paris 6, 75005, Paris, France. 3. Academic Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Vienna, Austria. 4. Academic Department of Urology, Tenon Hospital, APHP, 75020, Paris, France. 5. Academic Department of Urology, CHU Rennes and University of Rennes, Rennes, France. 6. Academic Department of Radiology, Pitié Salpêtrière Hospital, APHP, 75013, Paris, France. 7. Department of Urology, La Louvière Private Hospital, Lille, France. 8. Academic Department of Urology, Pitié-Salpêtrière Hospital, APHP, 47-83 boulevard de l'hopital, 75013, Paris, France. morgan.roupret@psl.aphp.fr. 9. GRC - UPMC n° 5, ONCOTYPE-URO, Institut Universitaire de Cancérologie, UPMC University Paris 6, 75005, Paris, France. morgan.roupret@psl.aphp.fr.
Abstract
PURPOSE: To review the contemporary data on the role of lymph node dissection (LND) at the time of radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC). METHODS: A computerized bibliographic search using the following protocol ("Nephroureterectomy") AND ("Lymphadenectomy" OR "Lymph node" OR "Lymphatic") was performed in MEDLINE to identify all original and review articles that addressed the role of LND for UTUC. RESULTS: Regional lymph node (LN) boundaries of UTUC have been recently investigated in mapping studies to propose anatomic templates of LND according to the laterality and location of primary tumor. Although these anatomic templates remained poorly described, most reports supported the staging benefit of LND that allowed for risk stratification of patients with (pN+) or without (pN0) LN metastases from those who did not undergo such a procedure (pNx). In addition, the therapeutic benefit of LND at the time of RNU was supported by better oncological outcomes obtained after complete LND when compared to incomplete or no LND, especially in the group of patients with advanced disease. The number of LNs removed was also correlated with both, more accurate staging and greater cancer-specific survival after LND, whose feasibility and safety have been validated in prospective studies. CONCLUSIONS: Despite mostly based on data with level of evidence 3, our comprehensive review of the literature supports the staging and therapeutic benefits of LND at the time of RNU for UTUC, which are particularly significant for patients with muscle-invasive or locally advanced disease.
PURPOSE: To review the contemporary data on the role of lymph node dissection (LND) at the time of radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC). METHODS: A computerized bibliographic search using the following protocol ("Nephroureterectomy") AND ("Lymphadenectomy" OR "Lymph node" OR "Lymphatic") was performed in MEDLINE to identify all original and review articles that addressed the role of LND for UTUC. RESULTS: Regional lymph node (LN) boundaries of UTUC have been recently investigated in mapping studies to propose anatomic templates of LND according to the laterality and location of primary tumor. Although these anatomic templates remained poorly described, most reports supported the staging benefit of LND that allowed for risk stratification of patients with (pN+) or without (pN0) LN metastases from those who did not undergo such a procedure (pNx). In addition, the therapeutic benefit of LND at the time of RNU was supported by better oncological outcomes obtained after complete LND when compared to incomplete or no LND, especially in the group of patients with advanced disease. The number of LNs removed was also correlated with both, more accurate staging and greater cancer-specific survival after LND, whose feasibility and safety have been validated in prospective studies. CONCLUSIONS: Despite mostly based on data with level of evidence 3, our comprehensive review of the literature supports the staging and therapeutic benefits of LND at the time of RNU for UTUC, which are particularly significant for patients with muscle-invasive or locally advanced disease.
Authors: Ricardo L Favaretto; Shahrokh F Shariat; Caroline Savage; Guilherme Godoy; Daher C Chade; Matthew Kaag; Bernard H Bochner; Jonathan Coleman; Guido Dalbagni Journal: BJU Int Date: 2011-06-01 Impact factor: 5.588
Authors: Maximilian Burger; Shahrokh F Shariat; Hans-Martin Fritsche; Juan Ignacio Martinez-Salamanca; Kazumasa Matsumoto; Thomas F Chromecki; Vincenzo Ficarra; Wassim Kassouf; Christian Seitz; Armin Pycha; Stefan Tritschler; Thomas J Walton; Giacomo Novara Journal: World J Urol Date: 2011-06-01 Impact factor: 4.226
Authors: Ross J Mason; Wassim Kassouf; David G Bell; Louis Lacombe; Anil Kapoor; Niels Jacobsen; Adrian Fairey; Jonathan Izawa; Peter Black; Simon Tanguay; Joseph Chin; Alan So; Jean-Baptiste Lattouf; Fred Saad; Edward Matsumoto; Darrel Drachenberg; Ilias Cagiannos; Yves Fradet; Ricardo A Rendon Journal: Urology Date: 2012-02-25 Impact factor: 2.649
Authors: Adil Ouzzane; Pierre Colin; Tarek P Ghoneim; Marc Zerbib; Alexandre De La Taille; François Audenet; Fabien Saint; Nicolas Hoarau; Emilie Adam; Marie Dominique Azemar; Henri Bensadoun; Luc Cormier; Olivier Cussenot; Alain Houlgatte; Gilles Karsenty; Charlotte Maurin; François Xavier Nouhaud; Véronique Phe; Thomas Polguer; Mathieu Roumiguié; Alain Ruffion; Morgan Rouprêt Journal: World J Urol Date: 2012-12-11 Impact factor: 4.226
Authors: Giacomo Novara; Vincenzo De Marco; Fedra Gottardo; Orietta Dalpiaz; Vianney Bouygues; Antonio Galfano; Guido Martignoni; Jean Jacques Patard; Walter Artibani; Vincenzo Ficarra Journal: Cancer Date: 2007-10-15 Impact factor: 6.860
Authors: Sandhya R Rao; Jose J Correa; Wade J Sexton; Julio M Pow-Sang; Shohreh I Dickinson; Hui-Yi Lin; Philippe E Spiess Journal: BJU Int Date: 2012-05-04 Impact factor: 5.588
Authors: Mounsif Azizi; Salim K Cheriyan; Charles C Peyton; Beat Foerster; Shahrokh F Shariat; Philippe E Spiess Journal: Curr Treat Options Oncol Date: 2019-04-01
Authors: Bjarte Almås; Stein Øverby; Ole J Halvorsen; Lars A R Reisæter; Jørg Assmus; Birgitte Carlsen; Anders Loe; Christian Beisland Journal: World J Urol Date: 2019-05-23 Impact factor: 4.226
Authors: Marco Moschini; Beat Foerster; Mohammad Abufaraj; Francesco Soria; Thomas Seisen; Morgan Roupret; Pierre Colin; Alexandre De la Taille; Benoit Peyronnet; Karim Bensalah; Roman Herout; Manfred Peter Wirth; Vladimir Novotny; Piotr Chlosta; Marco Bandini; Francesco Montorsi; Giuseppe Simone; Michele Gallucci; Giuseppe Romeo; Kazumasa Matsumoto; Pierre Karakiewicz; Alberto Briganti; Shahrokh F Shariat Journal: World J Urol Date: 2017-02-28 Impact factor: 4.226
Authors: Daniel Benamran; Thomas Seisen; Elias Naoum; Christophe Vaessen; Jérome Parra; Pierre Mozer; Shahrokh F Shariat; Morgan Rouprêt Journal: Transl Androl Urol Date: 2020-08